Verification evidence is still being completed.
PDF / print export
Valo Therapeutics
Helsinki, Finland
- Verified lead
- Paul Higham
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Cancer Immunotherapy, Oncolytic Viruses, Vaccine Vectors, and Translational Therapeutics
- Review cycle
- May 2026
- Full address
- Helsinki, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Valo Therapeutics announcement confirming Valo Therapeutics Oy in Helsinki, Finland.
- Editorial note
- Valo Therapeutics is published because official company materials confirm current leadership and explicitly identify the Finnish Helsinki operating company behind the immunotherapy platform.
Cancer Immunotherapy, Oncolytic Viruses, Vaccine Vectors, and Translational Therapeutics
Official leadership disclosure, Official Helsinki operating-company disclosure, Clinical immunotherapy platform claim
Valo Therapeutics is published because official company materials confirm current leadership and explicitly identify the Finnish Helsinki operating company behind the immunotherapy platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Helsinki, Finland
Valo Therapeutics
Cancer Immunotherapy, Oncolytic Viruses, Vaccine Vectors, and Translational Therapeutics · Clinical-stage therapeutics platform
Valo Therapeutics runs immunotherapy development, oncolytic virus platform, and cancer vaccine design in Helsinki, Finland.
- Lead
- Paul Higham (verified ↗)
- Address
- Helsinki, Finland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Immunotherapy Development · Oncolytic Virus Platform · Cancer Vaccine Design
- Founded
- 2016
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Paul Higham
CEO
Full addressHelsinki, Finland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Valo Therapeutics announcement explicitly identifying Valo Therapeutics Oy in Helsinki, Finland.
Open sourceClinical-stage therapeutics platform
Helsinki, Finland. Cancer Immunotherapy, Oncolytic Viruses, Vaccine Vectors, and Translational Therapeutics. Review completed on 21 Mar 2026.
Finnish and international clinical-development oversight
Official leadership disclosure, Official Helsinki operating-company disclosure, Clinical immunotherapy platform claim
Cancer Immunotherapy, Oncolytic Viruses, Vaccine Vectors, and Translational Therapeutics
Valo Therapeutics is published because official company materials confirm current leadership and explicitly identify the Finnish Helsinki operating company behind the immunotherapy platform.
Editorial note
Valo Therapeutics is published because official company materials confirm current leadership and explicitly identify the Finnish Helsinki operating company behind the immunotherapy platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Immunotherapy Development
Oncolytic Virus Platform
Cancer Vaccine Design
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Immunotherapy development workflow
Oncolytic virus platform
Clinical translation systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Valo Therapeutics located?
- Valo Therapeutics operates from Helsinki, Finland, Helsinki, Finland.
- Who runs Valo Therapeutics?
- Valo Therapeutics is led by Paul Higham, CEO. Verified 21 Mar 2026.
- What does Valo Therapeutics do?
- Valo Therapeutics runs immunotherapy development, oncolytic virus platform, and cancer vaccine design in Helsinki, Finland. Core capabilities: Immunotherapy Development, Oncolytic Virus Platform, Cancer Vaccine Design.
Editorial context
Related technical briefs
Briefs that name Helsinki as a covered market or city.